Cardiac Safety in Breast Cancer Patients Receiving Pegylated Liposome Doxorubicin Sequential Anti-HER2 Monoclonal Antibody Therapy

Background: Cardiotoxicity associated with the sequential use of anthracyclines followed by trastuzumab is common in adjuvant therapy of patients with HER2-positive early breast cancer (eBC). However, the cardiac safety of trastuzumab concurrent with pegylated liposomal doxorubicin (PLD) is relative...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Ping, Huang, Jia-huan, Zheng, Ya-bing, Cao, Wen-ming, Shao, Xi-ying, Chen, Jun-qing, Huang, Yuan, Li, Guang-liang, Sharma, K, Zhou, Huan-huan, Wang, Xiao-jia, Jin, Hong-chuan, Chen, Zhan-hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9386561/
https://www.ncbi.nlm.nih.gov/pubmed/35991878
http://dx.doi.org/10.3389/fphar.2022.883600

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9386561/
https://www.ncbi.nlm.nih.gov/pubmed/35991878
http://dx.doi.org/10.3389/fphar.2022.883600

Ejemplares similares